CytomX Therapeutics (NASDAQ: CTMX) reported Q3 EPS of $0.04, $0.23 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $26.38 million versus the consensus estimate of $13.34 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.